Andrew W. Greaves

发表

The TOKEn project: knowledge synthesis for in silico science

Stephen L. James, Philip R. O. Payne, Tara Borlawsky, 2011, J. Am. Medical Informatics Assoc..

CRC Tissue Core Management System (TCMS): Integration of Basic Science and Clinical Data for Translational Research

Philip R. O. Payne, Andrew W. Greaves, Laura Rassenti, 2003, AMIA.

CRC Clinical Trials Management System (CTMS): An Integrated Information Management Solution for Collaborative Clinical Research

Philip R. O. Payne, Andrew W. Greaves, Thomas J. Kipps, 2003, AMIA.

Supporting the Design of Translational Clinical Studies through the Generation and Verification of Conceptual Knowledge-anchored Hypotheses

Philip R. O. Payne, Tara Borlawsky, Alan Kwok, 2008, AMIA.

Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection.

Andrew W. Greaves, Emanuela M. Ghia, J. Byrd, 2008, Blood.

Ontology-anchored Approaches to Conceptual Knowledge Discovery in a Multi-dimensional Research Data Repository

Philip R. O. Payne, Rakesh Dhaval, Philip R.O. Payne, 2008, Summit on translational bioinformatics.

Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.

Andrew W. Greaves, D. Neuberg, L. Rassenti, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

leukemogenic selection high-risk disease and reflects antigen-driven, post-germinal-center Use of IGHV3-21 in chronic lymphocytic leukemia is associated with

Andrew W. Greaves, J. Byrd, J. Gribben, 2013 .

Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium.

Andrew W. Greaves, J. Byrd, D. Neuberg, 2010, Cancer genetics and cytogenetics.

Kinetic Measurement of Leukemia-Cell Proliferation Rate By Deuterium Labeling Predicts Time to Initial Treatment of Patients with Chronic Lymphocytic Leukemia

Andrew W. Greaves, J. Byrd, D. Neuberg, 2014 .

Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia

Andrew W. Greaves, J. Byrd, D. Neuberg, 2017, Leukemia.

Relative Value of CD38 and ZAP-70 Versus Immunoglobulin Mutation Status in Predicting Early Disease Progression in Chronic Lymphocytic Leukemia.

Andrew W. Greaves, J. Byrd, J. Gribben, 2006 .

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.

Arthur Weiss, Michael J Keating, Andrew W. Greaves, 2004, The New England journal of medicine.

Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.

Andrew W. Greaves, M. Grever, J. Byrd, 2014, Blood.

Cyclic nucleotide phosphodiesterase 7B mRNA: An unfavorable characteristic in chronic lymphocytic leukemia

Andrew W. Greaves, L. Rassenti, T. Kipps, 2011, International journal of cancer.

Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.

Sonia Jain, Feng He, Michael J Keating, 2008, Blood.

The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience

Andrew W. Greaves, D. Neuberg, P. D. Dal Cin, 2016, British journal of haematology.

Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study.

Andrew W. Greaves, J. Byrd, P. D. Dal Cin, 2010, Cancer genetics and cytogenetics.

Self‐administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia

Andrew W. Greaves, J. Gribben, D. Neuberg, 2011, Cancer.

Characteristics of Familial CLL Evaluated in the CLL Research Consortium Cohort

Andrew W. Greaves, M. Grever, J. Byrd, 2008 .

Lenalidomide Administered for the Initial Treatment of Chronic Lymphocytic Leukemia (CLL) Patients- In Vivo Modulation of the Leukemia Cell Surface Phenotype and Association with Tumor Flare Reaction (TFR).

Andrew W. Greaves, L. Rassenti, T. Kipps, 2009 .

Self-Administered, Subcutaneous (SQ) Alemtuzumab To Eliminate Residual Disease in Patients (pts) with CLL.

Andrew W. Greaves, J. Gribben, D. Neuberg, 2006 .

Lenalidomide and Rituximab for the Initial Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) A Multicenter Study of the CLL Research Consortium

Andrew W. Greaves, D. Neuberg, L. Rassenti, 2011 .

CLL-Cell Proliferation Measured by In Vivo Deuterium Labeling in Early Stage Patients and Correlation with Other Prognostic Markers.

Andrew W. Greaves, L. Rassenti, T. Kipps, 2007 .

Population-Based Evaluation of Postacute Coronavirus Disease-2019 (COVID-19) Chronic Sequelae in Patients Who Tested Positive for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

Amy M. Sitapati, Andrew W. Greaves, C. Longhurst, 2022, Open forum infectious diseases.

Andrew W. Greaves, D. Neuberg, L. Rassenti, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.